Randomized, open-label, multicenter phase 3 study to assess the efficacy and safety of GIVinostat versus hydroxyurea IN JAK2V617F-positive high-risk Polycythemia Vera patients: the GIV-IN PV TRIAL
RecruitingCTIS2022-502276-23-00
Italfarmaco S.p.A.JAK2V617F-positive high-risk Polycythemia Vera
Start: 2024-04-25Target: 219Updated: 2025-06-03